Eko Health

Eko Health develops FDA-cleared digital stethoscope technology enhanced with artificial intelligence algorithms for cardiovascular disease detection. The company's product line includes digital attachments for existing stethoscopes and complete digital stethoscope systems, complemented by their SENSORA platform for AI-enabled cardiac screening. With over 700,000 devices sold and 9 FDA clearances, Eko serves more than 600,000 healthcare providers across clinical settings.

The company's technology combines digitally enhanced audio with active noise cancellation, 3-lead ECG capabilities, and FDA-cleared AI algorithms that detect heart murmurs, atrial fibrillation, and low ejection fraction. Their platform features up to 40x amplification, automatic record keeping, and integration capabilities for telehealth and health system-wide deployment. Clinical validation across 60+ publications supports their technology's effectiveness in various care settings.

Eko has expanded beyond individual provider tools to offer enterprise solutions for health systems and life science organizations conducting clinical trials. The company recently received CMS reimbursement approval for their SENSORA platform in outpatient settings and FDA clearance for their cardiac foundation model, positioning them at the intersection of medical device innovation and AI-enabled diagnostics.

Choose Eko Health when your organization needs validated, market-ready technology for improving cardiac disease detection rather than custom development. Their proven track record with 600,000+ providers and clinical evidence from 60+ publications reduces implementation risk compared to unproven solutions.

Expect a product-led approach with clear pricing tiers, established integration pathways for major health systems, and access to reimbursement mechanisms through recent CMS approvals. The company's focus on cardiac AI delivers specialized expertise in this clinical domain with multiple FDA-cleared algorithms.

Eko Health exclusively serves the healthcare market with medical devices specifically designed for clinical cardiac and pulmonary assessment. The company holds multiple FDA clearances for medical-grade diagnostic algorithms and has achieved CMS reimbursement approval for their SENSORA platform in hospital-associated outpatient settings.

Their client base spans primary care, emergency medicine, cardiology, and nephrology specialties across major health systems including Sutter Health and NCH. The company also serves pharmaceutical and life science organizations with cardiac safety monitoring solutions for clinical trials, demonstrating specialized healthcare expertise across provider and research contexts.

Primary care networks and health systems looking to systematically improve cardiac disease screening rates across their provider base. Emergency departments needing enhanced auscultation in high-noise environments. Pharmaceutical companies conducting cardiovascular clinical trials requiring standardized cardiac monitoring. Individual clinicians seeking advanced diagnostic capabilities with evidence-based AI decision support.